Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018081695) COMPOSITONS AND METHODS FOR THE TREATMENT OF CANCER
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/081695 International Application No.: PCT/US2017/059007
Publication Date: 03.05.2018 International Filing Date: 30.10.2017
IPC:
C07K 16/18 (2006.01) ,A61K 39/395 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Applicants:
LAIRD, Ite [US/US]; US
UNIVERSITY OF SOUTHERN CALIFORNIA [US/US]; 1150 South Olive Street, Suite 2300 Los Angeles, CA 90015, US
Inventors:
LAIRD, Ite; US
Agent:
KONSKI, Antoinette, F.; US
RAO, Photon; US
SHELTON, Daniel; US
LIU, Cliff; US
Priority Data:
62/414,58728.10.2016US
Title (EN) COMPOSITONS AND METHODS FOR THE TREATMENT OF CANCER
(FR) COMPOSITIONS ET PROCÉDÉS POUR LE TRAITEMENT DU CANCER
Abstract:
(EN) This disclosure provides compositions and methods for treating cancer or inducing an immune response to the cancer in a subject by administering to the subject an effective amount of an isoaspartylated protein or a fragment thereof or an antibody that binds specifically to an isoaspartylated protein or a fragment thereof. In another aspect, the disclosure also provides a pharmaceutical composition, comprising, consisting essentially of, or yet further consisting of an effective amount of the isoaspartylated protein or a fragment thereof or antibody that binds specifically to an isoaspartylated protein or a fragment thereof; and a pharmaceutically acceptable carrier.
(FR) La présente invention concerne des compositions et des procédés pour le traitement du cancer ou l'induction d'une réponse immunitaire au cancer chez un sujet par l'administration au sujet d'une quantité efficace d'une protéine isoaspartylée ou d'un fragment de celle-ci ou d'un anticorps qui se lie spécifiquement à une protéine isoaspartylée ou à un fragment de celle-ci. Selon un autre aspect, l'invention concerne également une composition pharmaceutique, comportant, constituée essentiellement, ou encore constituée d'une quantité efficace de la protéine isoaspartylée ou d'un fragment de celle-ci ou d'un anticorps qui se lie spécifiquement à une protéine isoaspartylée ou à un fragment de celle-ci; et un support pharmaceutiquement acceptable.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)